Managing Side Effects

As with all medicines, you may feel side effects with Yurpeak®1

The most frequently reported adverse reactions in a clinical trial were gastrointestinal disorders, including nausea, diarrhea, constipation, and vomiting. In general, these reactions were mostly mild or moderate in severity and occurred more often during dose escalation and decreased over time.1

Tips for managing gastrointestinal symptoms

If you have nausea after taking Yurpeak®, talk to your doctor. In the meantime, these tips may help:

  • Eat smaller, more frequent meals2
  • At mealtimes, focus on recognizing when you feel full so you know when to stop eating. This may help you manage or prevent gastrointestinal symptoms3
  • Avoid foods and beverages which might worsen symptoms, such as high-fat or fried foods, spicy foods, alcohol, or carbonated beverages, to help reduce symptoms like nausea and heartburn3
  • Stay hydrated and gradually incorporate more fiber into your diet to help reduce constipation 3

Dehydration 2

  • When starting your medicine, you may experience loss of fluids/ dehydration (due to vomiting, nausea, and/or diarrhea), which may lead to decreased kidney function
  • It is important to avoid dehydration by drinking plenty of fluids

Hypoglycaemia 1,2

  • Yurpeak® itself has a low risk of causing hypoglycemia, or low blood sugar
  • If you are taking a type of drug called sulfonylurea or insulin, you have a higher chance of getting hypoglycemia
  • Your doctor may decide to lower your dose of these medicines before adding Yurpeak to your treatment

Throughout a 72-week study of 2539 adults with obesity or with overweight and a weight-related complication without diabetes, people taking Yurpeak® experienced significant weight. loss. Individual results may vary.

*Yurpeak® is not approved for the treatment of high cholesterol, high triglycerides, or high blood pressure. Changes occurred during a 72-week clinical trial in people who followed a reduced-calorie diet, increased their physical activity and took Yurpeak®.

References 1. Yurpeak (tirzepatide once weekly) India Prescribing Information | March 2025. 2. Gorgojo-Martinéz JJ, Mezquita-Raya P, Carretero-Gómez J, et al. Clinical recommendations to manage gastrointestinal adverse events in patients treated with GLP-1 receptor agonists: a multidisciplinary expert consensus. J Clin Med. 2023;12:145. doi:10.3390/jcm12010145 3. Wharton S, Davies M, Dicker D, et al. Managing the gastrointestinal side effects of GLP-1 receptor agonists in obesity: recommendations for clinical practice. Postgrad Med. 2022;134:14-19. doi:10.1080/ 00325481.2021.2002616
Learn about additional support options
MORE SUPPORT
Disclaimers: This initiative is solely for patient support. It has been created with an intention to provide, assistance and support to patients & NOT intended towards product promotion, NOR advertisement of any health care professionals or doctors.  Patients should be advised to consult and seek medical advice from their concerned doctor/ health care professional before starting any treatment/medicine/ diet plan. Any advice regarding the management of any medical condition is completely at the discretion of their consulting physician/doctor (Registered Medical Practitioner). Cipla limited makes no representations as to the efficacy, accuracy, appropriateness, or suitability of any specific tests, products, procedures, treatments, services, opinions, healthcare providers or other information that may be shared through this screening/program/activity. Cipla shall not be responsible for any direct, indirect, consequential or other damages arising therefrom. No personal data is being collected, stored, or processed by Cipla as a part of this initiative. Yurpeak®, KwikPen® and Lilly are registered trademark of Eli Lilly & Company, promoted and distributed by Cipla in India. The “CIPLA” mark and logo are the sole and intellectual property of Cipla Limited. Nothing on this website should be construed as giving medical advice or making recommendations regarding any health-related decision or action. You should consult a doctor or other qualified healthcare professional regarding any questions about your health or before making any treatment-related decisions. The contents of this site are not intended to substitute the medical judgment of your treating physicians. This website is intended for people over 18 years of age. This website is intended for the sole use of registered health care providers and patients prescribed with Yurpeak (tirzepatide) on their physician's advice. Yurpeak and its delivery device base are registered trademarks owned or licensed by Eli Lilly and Company, its subsidiaries, or affiliates. Yurpeak is available by prescription only. To be sold by retail under prescription of Endocrinologist or Internal Medicine specialists only. For adverse events and safety reporting, please reach out to: drugsafety@cipla.com or report to Cipla Ltd. on 18002577779 For any additional information related to Lilly products, please reach out to: queries_in-medinfo@lilly.com.